Cellestetix Secures $2 Million for Plant-Based Beauty Breakthrough
%2Fuploads%2Fpr%2520articles%2F2024%2F08%2F21_1cellestetix.jpg&w=3840&q=75)
Biotechnology company Cellestetix, which specializes in discovering, developing, and commercializing plant-based exosome formulations for regenerative beauty treatments, has secured $2 million in funding. The investment round was led by Pragma Capital Partners (PCP) and included participation from APY Ventures, Arya Ventures, Maxis Ventures, İstCapital, Ahmet Ramiz, and other angel investors.
This new capital will accelerate Cellestetix’s growth in the U.S. market and support its ongoing product development initiatives.
Founded by two female genetic engineers, Dr. Polen Koçak and Dr. Merve Yıldırım, who have over a decade of experience in biotechnology, genetics, bioengineering, and gene therapy, Cellestetix originally operated as an R&D platform for cancer and wound care. However, the company's focus shifted towards cosmetic applications of plant-based exosomes under the SickScience brand following the addition of former Estee Lauder executives to the management team.
SickScience Labs, a brand developed by Cellestetix, offers plant-based exosome formulations aimed at skin rejuvenation and beauty care. Since entering the U.S. market in early 2024, SickScience products have gained recognition in prestigious media outlets such as WWD, People Magazine, The Today Show, and Forbes.
Cellestetix plans to establish SickScience Labs, Inc. as an independent brand in the U.S., with research and development of exosomes conducted in Turkey, while final product manufacturing and marketing are handled in the U.S.
Source: Gözde Ulukan / Webrazzi
Cellestetix
Cellestetix is a biotechnology company focused on the discovery, development, and commercialization of plant-based exosome technology, an entirely new way to treat skin, hair, and wellness at the molecular level, offering customers the next frontier in regenerative biology.
%2Fuploads%2Fcrypto-universe%2FThe-Crypto-Universe-cover.jpg&w=3840&q=75)
%2Fuploads%2Fvideos%2Fmenapt-top-5%2FMENAPT_Nov2024.jpg&w=3840&q=75)
%2Fuploads%2Fcrypto-universe%2Fvideo%2Fvideo5.jpg&w=3840&q=75)
%2Fuploads%2Fcrypto-universe%2Fvideo%2Fvideo3.jpg&w=3840&q=75)
%2Fuploads%2Fcrypto-universe%2Fvideo%2Fvideo2.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2024%2F09%2F24_3chitosolve.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2024%2F09%2F02_3pilgrim.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2024%2F08%2F27_3powderbeauty.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F01%2F14_sigma.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2024%2F10%2F18_3eruditus.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2024%2F10%2F16_3ubeya.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2024%2F10%2F16_1aila.jpg&w=3840&q=75)
%2Fuploads%2Fnewsletter%2F2024%2F1016_3a.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2024%2F10%2F15_1lidwave.jpg&w=3840&q=75)
%2Fuploads%2Farticles%2F2024%2F1013_turkey-unicorns-2024%2Fcover.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F03%2F12_1lwh.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F02%2F20_1blockaid.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F02%2F16_2exeromedical.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F02%2F05_7dreamfly.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F02%2F05_3pluri.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F01%2F28_1maalexi.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F01%2F27_2biosapien.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F01%2F08_6senseera.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2024%2F12%2F17_1invoiceq.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2024%2F12%2F13_1quantix.jpg&w=3840&q=75)
